Literature DB >> 33512409

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study.

Niloufer Khan1, Sarah Lindner2, Antonio L C Gomes2, Sean M Devlin3, Gunjan L Shah1,4, Anthony D Sung5, Craig S Sauter1,4, Heather J Landau1,4, Parastoo B Dahi1,4, Miguel-Angel Perales1,4, David J Chung1,4, Alexander M Lesokhin4,6, Anqi Dai2, Annelie Clurman1, John B Slingerland1, Ann E Slingerland1, Daniel G Brereton1, Paul A Giardina1, Molly Maloy1, Gabriel K Armijo2, Carlos Rondon-Clavo1, Emily Fontana2, Lauren Bohannon5, Sendhilnathan Ramalingam5, Amy T Bush5, Meagan V Lew5, Julia A Messina7, Eric Littmann8, Ying Taur4,9, Robert R Jenq10, Nelson J Chao5, Sergio Giralt1,4, Kate A Markey1,4, Eric G Pamer8, Marcel R M van den Brink1,2,4, Jonathan U Peled1,4.   

Abstract

We previously described clinically relevant reductions in fecal microbiota diversity in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Recipients of high-dose chemotherapy and autologous HCT (auto-HCT) incur similar antibiotic exposures and nutritional alterations. To characterize the fecal microbiota in the auto-HCT population, we analyzed 1161 fecal samples collected from 534 adult recipients of auto-HCT for lymphoma, myeloma, and amyloidosis in an observational study conducted at 2 transplantation centers in the United States. By using 16S ribosomal gene sequencing, we assessed fecal microbiota composition and diversity, as measured by the inverse Simpson index. At both centers, the diversity of early pretransplant fecal microbiota was lower in patients than in healthy controls and decreased further during the course of transplantation. Loss of diversity and domination by specific bacterial taxa occurred during auto-HCT in patterns similar to those with allo-HCT. Above-median fecal intestinal diversity in the periengraftment period was associated with decreased risk of death or progression (progression-free survival hazard ratio, 0.46; 95% confidence interval, 0.26-0.82; P = .008), adjusting for disease and disease status. This suggests that further investigation into the health of the intestinal microbiota in auto-HCT patients and posttransplant outcomes should be undertaken.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 33512409      PMCID: PMC7976512          DOI: 10.1182/blood.2020006923

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  67 in total

1.  Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease.

Authors:  Robert R Jenq; Ying Taur; Sean M Devlin; Doris M Ponce; Jenna D Goldberg; Katya F Ahr; Eric R Littmann; Lilan Ling; Asia C Gobourne; Liza C Miller; Melissa D Docampo; Jonathan U Peled; Nicholas Arpaia; Justin R Cross; Tatanisha K Peets; Melissa A Lumish; Yusuke Shono; Jarrod A Dudakov; Hendrik Poeck; Alan M Hanash; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Eric G Pamer; Marcel R M van den Brink
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-11       Impact factor: 5.742

2.  Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.

Authors:  Zachariah DeFilipp; Jonathan U Peled; Shuli Li; Jasmin Mahabamunuge; Zeina Dagher; Ann E Slingerland; Candice Del Rio; Betsy Valles; Maria E Kempner; Melissa Smith; Jami Brown; Bimalangshu R Dey; Areej El-Jawahri; Steven L McAfee; Thomas R Spitzer; Karen K Ballen; Anthony D Sung; Tara E Dalton; Julia A Messina; Katja Dettmer; Gerhard Liebisch; Peter Oefner; Ying Taur; Eric G Pamer; Ernst Holler; Michael K Mansour; Marcel R M van den Brink; Elizabeth Hohmann; Robert R Jenq; Yi-Bin Chen
Journal:  Blood Adv       Date:  2018-04-10

3.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Authors:  Michel Attal; Valerie Lauwers-Cances; Cyrille Hulin; Xavier Leleu; Denis Caillot; Martine Escoffre; Bertrand Arnulf; Margaret Macro; Karim Belhadj; Laurent Garderet; Murielle Roussel; Catherine Payen; Claire Mathiot; Jean P Fermand; Nathalie Meuleman; Sandrine Rollet; Michelle E Maglio; Andrea A Zeytoonjian; Edie A Weller; Nikhil Munshi; Kenneth C Anderson; Paul G Richardson; Thierry Facon; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau
Journal:  N Engl J Med       Date:  2017-04-06       Impact factor: 91.245

4.  Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study.

Authors:  Najla El Jurdi; Ali Filali-Mouhim; Iman Salem; Mauricio Retuerto; Nina Margaret Dambrosio; Linda Baer; Hillard M Lazarus; Paolo Caimi; Brenda Cooper; Benjamin Tomlinson; Leland Metheny; Ehsan Malek; Folashade Otegbeye; Rafick-Pierre Sekaly; Mahmoud Ghannoum; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2019-04-05       Impact factor: 5.742

5.  BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.

Authors:  Jae-Cheol Jo; Byung Wook Kang; Geundoo Jang; Sun Jin Sym; Sung Sook Lee; Ja Eun Koo; Jong Wook Kim; Shin Kim; Jooryung Huh; Cheolwon Suh
Journal:  Ann Hematol       Date:  2007-08-21       Impact factor: 3.673

6.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

7.  Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

Authors:  N Chaput; P Lepage; C Coutzac; E Soularue; K Le Roux; C Monot; L Boselli; E Routier; L Cassard; M Collins; T Vaysse; L Marthey; A Eggermont; V Asvatourian; E Lanoy; C Mateus; C Robert; F Carbonnel
Journal:  Ann Oncol       Date:  2017-06-01       Impact factor: 32.976

8.  Structure, function and diversity of the healthy human microbiome.

Authors: 
Journal:  Nature       Date:  2012-06-13       Impact factor: 49.962

9.  Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Authors:  Tulio E Rodriguez; Parameswaran Hari; Patrick J Stiff; Scott E Smith; Danielle Sterrenberg; David H Vesole
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-07       Impact factor: 5.742

10.  Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.

Authors:  Arthur E Frankel; Laura A Coughlin; Jiwoong Kim; Thomas W Froehlich; Yang Xie; Eugene P Frenkel; Andrew Y Koh
Journal:  Neoplasia       Date:  2017-09-15       Impact factor: 5.715

View more
  4 in total

1.  Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma.

Authors:  Maren Schmiester; René Maier; René Riedel; Pawel Durek; Marco Frentsch; Stefan Kolling; Mir-Farzin Mashreghi; Robert Jenq; Liangliang Zhang; Christine B Peterson; Lars Bullinger; Hyun-Dong Chang; Il-Kang Na
Journal:  Gut Microbes       Date:  2022 Jan-Dec

2.  Antibiotic Exposure, Not Alloreactivity, Is the Major Driver of Microbiome Changes in Hematopoietic Cell Transplantation.

Authors:  Rajat Bansal; Heekuk Park; Cristian C Taborda; Christian Gordillo; Markus Y Mapara; Amer Assal; Anne-Catrin Uhlemann; Ran Reshef
Journal:  Transplant Cell Ther       Date:  2021-12-24

3.  Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?

Authors:  Simone A Minnie; Geoffrey R Hill
Journal:  Front Immunol       Date:  2021-03-12       Impact factor: 7.561

Review 4.  The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma.

Authors:  Arianna Brevi; Laura Lucia Cogrossi; Marco Lorenzoni; Benedetta Mattorre; Matteo Bellone
Journal:  Front Immunol       Date:  2022-03-17       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.